Trials / Conditions / Relapsed T-Cell Lymphoma

Relapsed T-Cell Lymphoma

8 registered clinical trials studyying Relapsed T-Cell Lymphoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605	Masonic Cancer Center, University of Minnesota	Phase 2
Terminated	CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma NCT04217317	Wake Forest University Health Sciences	Phase 2
Terminated	Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH NCT04251065	Fondazione Italiana Linfomi - ETS	Phase 2
Completed	Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Active Not Recruiting	Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory NCT03349333	Mundipharma (China) Pharmaceutical Co. Ltd	Phase 3
Terminated	A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma NCT01878708	Dana-Farber Cancer Institute	EARLY_Phase 1